Charles River Labs Beats Q3 Expectations, Raises Guidance

Charles River Laboratories reported a flat Q3 2025 revenue of $1B, slightly beating analyst estimates, but with a 4% higher adjusted profit of $2.43 per share. Despite a stable year-over-year sales, the company's operating margin improved to 13.3% from 11.6% in Q3 2024, indicating better cost management. The CEO, James C. Foster, expressed optimism about stable demand and potential industry recovery, but cautioned about ongoing healthcare sector uncertainty. The company raised its full-year adjusted earnings per share guidance, while analysts expect modest revenue growth. The stock remained relatively flat post-announcement, reflecting a mixed market reaction.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.